Understanding and Communicating the Benefits and Risks ofDenosumab, Raloxifene, and Teriparatide for the Treatment ofOsteoporosis

Journal of Clinical Densitometry

Volumn 17, Issue 4, 2014, Pages 490-495

  Michael Lewiecki, E ^a   Miller, Paul D ^b   Harris, Steve T ^c   Bauer, Douglas C ^c   Shawn Davison, K ^d   Dian, Larry ^e   Hanley, David A ^f   McClung, Michael R ^g   Yuen, Chui K ^e   Kendler, David L ^e  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^b Health Sciences Center and Colorado Center for Bone Research   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF VICTORIA   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

Benefit; Fracture; Osteoporosis; Risk; Treatment

Indexed keywords

DENOSUMAB; PARATHYROID HORMONE[1-34]; RALOXIFENE; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY;

CELLULITIS; CEREBROVASCULAR ACCIDENT; DIZZINESS; ECZEMA; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INJECTION SITE INFECTION; LEG CRAMP; MEDICAL DECISION MAKING; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; THERAPY EFFECT; VENOUS THROMBOEMBOLISM; DOCTOR PATIENT RELATION; FEMALE; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATIENT EDUCATION; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; RALOXIFENE; RISK ASSESSMENT; TERIPARATIDE;

EID: 84925223372     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2013.09.018     Document Type: Review

References (41)

1. MacLean C., Newberry S., Maglione M., et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008, 148:197-213.
2. Gehlbach S.H., Fournier M., Bigelow C. Recognition of osteoporosis by primary care physicians. Am J Public Health 2002, 92:271-273.
3. Solomon D.H., Finkelstein J.S., Katz J.N., et al. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 2003, 115:398-400.
4. Cramer J.A., Gold D.T., Silverman S.L., Lewiecki E.M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007, 18:1023-1031.
5. Cramer J.A., Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006, 119:S12-S17.
6. McClung M., Harris S.T., Miller P.D., et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. AmJ Med 2013, 126:13-20.
7. Cummings S.R., San Martin J.A., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
8. Dowd R., Recker R.R., Heaney R.P. Study subjects and ordinary patients. Osteoporos Int 2000, 11:533-536.
9. Edwards A., Elwyn G. How should effectiveness of risk communication to aid patients' decisions be judged? A review of the literature. Med Decis Making 1999, 19:428-434.
10. Lewiecki E.M. Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom 2010, 13:335-345.
11. Lewiecki E.M. The role of risk communication in the care of osteoporosis. Curr Osteoporos Rep 2011, 9:141-148.
12. Ford S., Schofield T., Hope T. What are the ingredients for a successful evidence-based patient choice consultation?: A qualitative study. Soc Sci Med 2003, 56:589-602.
13. Papapoulos S., Chapurlat R., Libanati C., et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012, 27:694-701.
14. Orwoll E., Teglbjaerg C.S., Langdahl B.L., et al. A randomized, placebo-controlled study of the effects of denosumab forthe treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012, 97:3161-3169.
15. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
16. Brown J.P., Dempster D.W., Ding B., et al. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J Bone Miner Res 2011, 26:2737-2744.
17. Watts N.B., Roux C., Modlin J.F., et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?. Osteoporos Int 2012, 23:327-337.
18. Scott L.J., Muir V.J. Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours. Drugs 2011, 71:1059-1069.
19. Block G.A., Bone H.G., Fang L., et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012, 27:1471-1479.
20. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
21. Neele S.J., Evertz R., De Valk-De R.G., et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002, 30:599-603.
22. Barrett-Connor E., Grady D., Sashegyi A., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002, 287:847-857.
23. Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96:1751-1761.
24. Vogel V.G. Managing the risk of invasive breast cancer inwomen at risk for breast cancer and osteoporosis: the role of raloxifene. Clin Interv Aging 2008, 3:601-609.
25. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355:125-137.
26. Vestergaard P., Schwartz K., Pinholt E.M., et al. Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporos Int 2011, 22:1037-1045.
27. Cauley J.A., Norton L., Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001, 65:125-134.
28. Delmas P.D., Ensrud K.E., Adachi J.D., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002, 87:3609-3617.
29. Davies G.C., Huster W.J., Lu Y., et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999, 93:558-565.
30. Nakamura T., Sugimoto T., Nakano T., et al. Randomized teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012, 97:3097-3106.
31. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
32. Adami S., San M.J., Munoz-Torres M., et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment inpostmenopausal women with osteoporosis. Osteoporos Int 2008, 19:87-94.
33. Orwoll E.S., Scheele W.H., Paul S., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
34. Vahle J.L., Long G.G., Sandusky G., et al. Bone neoplasms inF344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426-438.
35. Harper K.D., Krege J.H., Marcus R., Mitlak B.H. Osteosarcoma and teriparatide?. J Bone Miner Res 2007, 22:334.
36. Subbiah V., Madsen V.S., Raymond A.K., et al. Of mice andmen: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 2010, 21:1041-1045.
37. Andrews E.B., Gilsenan A.W., Midkiff K., et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012, 27:2429-2437.
38. Miller P.D., Bilezikian J.P., Diaz-Curiel M., et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007, 92:3535-3541.
39. Lewiecki E.M., Bilezikian J.P., Khosla S., et al. Osteoporosis update from the 2010 santa fe bone symposium. J Clin Densitom 2011, 14:1-21.
40. Saag K.G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
41. Greenspan S.L., Bone H.G., Ettinger M.P., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146:326-339.